Seegene, Korean provider to develop molecular diagnostics for cancer

Manjula Puthenedam, PhD, | | Health Imaging | Oncology Imaging
Seegene has entered a partnership with Samsung Medical Center to co-develop molecular diagnostics for cancer.

In this partnership, Seegene will bring its molecular diagnostic technology and Samsung will offer its clinical and disease pathology expertise to the development of new cancer molecular diagnostics tests. Samsung will also provide the first test sites, according to Seegene, which is based in Seoul, Korea.

Seegene will develop new tests for drug resistance and Single Nucleotide Polymorphism (SNP) based on multiplex PCR technology and real-time PCR technology, which will detect genetic mutations indicative of certain cancers. The initial tests to be developed will be for nonsmall cell lung cancer, colon cancer, pancreatic cancer and cholangiocarcinoma. 

Oncologists will use these new molecular diagnostic tests to determine the genomic profile of a patient's tumor to understand if the patient is likely to respond to cancer therapies, such as tamoxifen or chemotherapy, or if the cancer will return or metastasize, added the company.

Manjula Puthenedam, PhD,

Related Content

High-intensity focused ultrasound could allow prostate cancer patients to avoid surgery
MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.